NCIC CLINICAL TRIALS GROUP

GYNECOLOGY

DISEASE SITE COMMITTEE MEETING AGENDA

EATON CHELSEA HOTEL, TORONTO, ON
ROOM: CHURCHILL B

SATURDAY MAY 3 2014 – 9:00 A.M. - 3:30 P.M.

CHAIRS: MICHAEL FUNG KEE FUNG AND HAL HIRTE
(3:30 P.M. – 4:15 P.M. EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:
To provide an understanding for the rationale for immunotherapy based trials

To provide an understanding of the management of high-risk endometrial cancer and the rationale for a novel targeted therapeutic approach to endometrial cancer

To further explore the concept of an integrated clinical trial and research platform in gynecologic cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m.</td>
<td><strong>Opening remarks and outline of the meeting</strong></td>
<td>M. Fung-Kee-Fung / H. Hirte</td>
</tr>
<tr>
<td></td>
<td>1. Review of minutes and follow-up items from Spring Meeting 2013</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Overview of Gyne Trials Landscape and update on ecosystem blueprint and roadmap</td>
<td></td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td><strong>Clinical Trial Updates</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. OV.21</td>
<td>D. Provencher / H. MacKay</td>
</tr>
<tr>
<td></td>
<td>2. CX.5 / SHAPE</td>
<td>M. Plante</td>
</tr>
<tr>
<td></td>
<td>3. EN.7 / PORTEC-3</td>
<td>A. Fyles</td>
</tr>
<tr>
<td></td>
<td>4. OV.18 (ICON-6)</td>
<td>H. Hirte</td>
</tr>
<tr>
<td></td>
<td>5. OV.19 (ICON-7)</td>
<td>A. Oza</td>
</tr>
</tbody>
</table>

10:30 a.m. **BREAK**
10:45 a.m  **Planned/Proposed Trials for Presentation and Feedback**
1. OV.23 (planned) A. Oza
2. Endometrial Basket Trial S. Welch
3. Ovary Prevention Study Proposal A. Oza
4. Innate NK and T cell checkpoint inhibitor in Ovary H. Hirte

12:00 p.m  **LUNCH**

1:30 p.m  **Educational Session**
1. Variations in Practice for the Management of High Risk Histologic Subtypes in Endometrial Cancer M. Bernardini
2. Immune Checkpoint Regulation: Opportunities in Gynecologic Malignancies M. Butler

2:30 p.m  **Working Group Updates**
1. Ovary D. Provencher / H. MacKay
2. Cervix M. Plante / C. Doll
3. Endometrium M. Bernardini / S. Welch
4. Correlative Sciences and Tumour Biology A. Mes-Masson / M. Butler

3:15 p.m  **Other Updates**
1. The patient’s role in trial participation M. Manojlovich
2. Other Gyne DSC Rep Reports
3. NCI US – GCSC and Ovarian Cancer Task Force
4. GCIG
5. Other

3:30 p.m  **ADJOURN**

*Closed meeting of Gyne Executive Council to follow in the Baker Room.*